Sage Journals: Discover world-class research

Abstract

The development of painful diabetic neuropathy (PDN) is a common complication of chronic diabetes that can be associated with significant disability and healthcare costs. Prompt symptom identification and aggressive glycemic control is essential in controlling the development of neuropathic complications; however, adequate pain relief remains challenging and there are considerable unmet needs in this patient population. Although guidelines have been established regarding the pharmacological management of PDN, pain control is inadequate or refractory in a high proportion of patients. Pharmacotherapy with anticonvulsants (pregabalin, gabapentin) and antidepressants (duloxetine) are common first-line agents. The use of oral opioids is associated with considerable morbidity and mortality and can also lead to opioid-induced hyperalgesia. Their use is therefore discouraged. There is an emerging role for neuromodulation treatment modalities including intrathecal drug delivery, spinal cord stimulation, and dorsal root ganglion stimulation. Furthermore, consideration of holistic alternative therapies such as yoga and acupuncture may augment a multidisciplinary treatment approach. This aim of this review is to focus on the current management strategies for the treatment of PDN, with a discussion of treatment rationale and practical considerations for their implementation.

Keywords

diabetes neuromodulation neuropathy pain painful diabetic neuropathy pharmacotherapy

Introduction

Approximately half of the estimated 425 million patients with diabetes worldwide will be affected by diabetic neuropathy.^1-4 Neuropathic complications reportedly comprise up to 27% of the cost of diabetes.⁵ Less easily quantified are the burdens of depression, lost productivity, and impaired quality-of-life suffered by patients.^6,7 Up to a third of patients with diabetes will also develop painful diabetic neuropathy (PDN), further exacerbating disability.^8,9 Thus, the treatment of PDN is focused on strict glycemic control to deter disease progression and pain management. In one study, patients with PDN spent US$7066 annually more than patients without pain, highlighting significant economic costs.¹⁰

Both the American Academy of Neurology¹¹ and European Federation of Neurological Societies¹² have published guidelines regarding the clinical management of PDN, although the randomized clinical trials (RCTs) forming the basis of these guidelines were generally based on short-term data.¹³ In the clinical setting, PDN often involves polypharmacy, which highlights the difficulty in obtaining pain relief with single medications.^14,15 This review focuses on the current management strategies for the treatment of PDN including pharmacological, neuromodulation, and alternative therapies.

Clinical Presentation and General Management

PDN is a clinical diagnosis, and there is considerable variability in its presentation.^1,4 Burning pain is often the initial presenting complaint, and concurrent paresthesias are common.^16,17 A distal, symmetric “stocking” distribution is the most common manifestation.¹⁷ Rarer atypical forms include diabetic radiculoplexopathies (often unilateral/asymmetric), chronic inflammatory demyelinating polyradiculoneuropathy, and autonomic neuropathies.¹⁷ These subtypes are less studied and can be particularly difficult to manage. Onset may be insidious, and therefore a careful history probing for less overt symptoms may be essential for diagnosis.¹

PDN is a diagnosis of exclusion; as such, other metabolic derangements and causes of peripheral neuropathy must be ruled out. This may be particularly difficult given the common associated comorbidities, including metabolic syndrome.¹⁶ To further complicate diagnosis, up to half of patients may be asymptomatic.¹ Therefore, the American Diabetes Association recommends temperature and monofilament testing to screen for neuropathy in patients initially diagnosed with type 2 diabetes, and within five years of a type 1 diabetes diagnosis.^1,18 Both subtypes should be tested annually after their initial evaluation, and some research has shown certain prediabetic patients should also be screened.^1,18

There are no proven treatments able to reverse the nerve damage; therefore, preventative measures including proper foot care and good glycemic control are the cornerstones of treatment.^1,2,4 Measures to slow or halt symptom progression include lifestyle modifications, such as an improved diet, exercise, and weight loss, as well as medications to optimize glycemic control.^17,19 Maintaining glycemic control has been associated with significantly lower incidence and slower progression of neuropathy, with particular benefit (up to 81% relative risk reduction) demonstrated in patients with type 1 diabetes.^19,20

Pain management is a particular challenge posed by PDN and an important treatment consideration.^14,21 For the remainder of this review, we will focus on PDN management and discuss accepted pharmacotherapies, neuromodulatory techniques, and alternative therapies used for pain relief. Figure 1 illustrates a flowchart of recommended management strategies.

Figure 1.

Flowchart of painful diabetic neuropathy management options.

Pharmacotherapy

It is a common misconception that all pain medications are to be taken “as needed.” While this may hold true for musculoskeletal pain, the management of neuropathic pain requires routine and regimented administration regardless of pain severity in order to provide sustained relief. Therefore, it is crucial that specialists in diabetes management educate patients on the need to adhere to the appropriate dosage regimen.

Current pharmacotherapeutic strategies include antidepressants, anticonvulsants, and opioids, which have been demonstrated to be superior to placebo for pain control in PDN.¹³ Other therapies such as topical analgesics and intravenous (IV) medications warrant further study. Published guidelines from the American Academy of Neurology recommend pregabalin as a first-line treatment.¹¹ In addition to pregabalin, first-line treatment recommendations from the European Federation of Neurological Societies include serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA), and gabapentin.¹² Table 1 outlines pharmacotherapeutic agents, including dose considerations, mechanisms, and side effects.^22,23

Table 1.

Pharmacotherapy for Painful Diabetic Neuropathy.

	Dose range	Starting dose	Dose escalation	Mechanism	Side effects	Notes
Pregabalin	150-600 mg	75 mg bid	Escalate to 150 mg bid within 1 week of initiation based on tolerability;Max Dose:300 mg bid	Inhibition of voltage gated calcium channel and ATP gated potassium channel	Dizziness, blurred vision, drowsiness.	NNT = 5-8; NNH = 9-16
Gabapentin	300-3600 mg	300 mg daily (Day 1)	Day 2: 300 mg bid; Day 3: 300 mg tid;Max Dose:1800-3600 mg/day in 3 divided doses.	Inhibition of voltage gated calcium channel	Confusion, dizziness, gastrointestinal issues, abnormal thinking	NNT = 3; NNH = 4
Duloxetine	60-120 mg	30 mg bid	Lower dose based on tolerability.Max Dose:60 mg/day.	SNRI	Gastrointestinal issues, somnolence, hyperhidrosis	NNT = 5; NNH = 17
Venlafaxine	37.5-225 mg	37.5 mg bid	Escalate to 150 mg daily:Max Dose:225 mg daily	SNRI or SSRI at low doses	Gastrointestinal issues, somnolence, hyperhidrosis, prolonged QT	NNT = 3; NNH = 16
Amitriptyline	10-150 mg	10 mg daily at bedtime	Max Dose:150 mg daily at bedtime	Inhibition of voltage-gated sodium channels, NDMA receptors, and reuptake of serotonin and norepinephrine	Gastrointestinal issues, orthostatic hypotension, dry mouth, urinary retention, and QTc prolongation.	NNT = 1-3; NNH = 28 (for major adverse effects), 6 (for minor adverse effects)
Tapentadol	100-250 mg	50 mg bid	Escalate to 100-250 mg bid as tolerated;Max Dose:250 mg bid	µ-opioid receptor agonist and norepinephrine reuptake inhibitor	Addiction, paradoxical hyperalgesia, respiratory depression, gastrointestinal issues.	NNT = 9-10; NNH = 5
Topical Capsaicin	0.075-8%	Apply 4 times daily	Not applicable	Vanilloid receptor agonist	Burning sensation and dermal irritation	NNT = 7
Topical Lidocaine	5%	1 patch every 12 hours	12-hour patch free interval.Max Dose:3 patches daily	Inhibition of voltage gated sodium channels.	Dermal irritation	NNT = 4
α-Lipoic acid	100-1800 mg	600 mg	Not applicable	Antioxidant	Nausea, gastrointestinal issues	Not studied.
Actovegin	600- 2000 mg	600 mg tid	Not applicable	Anti-hypoxic agent	Nausea	Not studied.

Abbreviations: bid, twice daily; NNH, number needed to harm; NNT, number needed to treat; SNRI, selective norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitors; tid, thrice daily.

Anticonvulsants

Pregabalin is a Food and Drug Administration (FDA)-approved anticonvulsant used for the management of PDN, administered daily at 150-600 mg. Evidence shows significant pain reduction with comparable efficacy to duloxetine and gabapentin,^24-27 as well as improvements in sleep and global impression scales without affecting nerve conduction.^26,28 Gabapentin is characterized as second-line therapy, typically administered at a total daily dose of 300-3600 mg.²⁹ It is well-tolerated, demonstrating up to 50% pain relief compared to placebo, and noninferior pain relief compared to amitriptyline and pregabalin.^30,31 At higher doses, both pregabalin and gabapentin are administered in divided doses.

Secondary to their pharmacokinetics, pain relief is observed within one to four weeks from initiation of either pregabalin or gabapentin.²³ During this time, however, side effects may be experienced including confusion, dizziness, drowsiness, and gastrointestinal issues.^26,32 The use of anticonvulsants is also associated with the development of tachyphylaxis. It is important to emphasize to patients to continue taking their medication in order for pain control to be realized, and dose adjustments can be made to balance pain relief and side effects. Furthermore, pregabalin is often cost-prohibitive or not commonly covered by insurance.

Other anticonvulsants for PDN management include carbamazepine, valproic acid, and lamotrigine. While these medications have demonstrated improvement in PDN symptoms, they are not first-line and have shown inconsistent results.^33-35

Antidepressants

Antidepressants, such as duloxetine, are considered first-line pharmacotherapy for PDN. While initially prescribed for depression, duloxetine is an SNRI that is widely studied in PDN management, and is prescribed as a daily dose of 60-120 mg. Duloxetine improves long-term pain outcomes, depressive symptoms, and overall quality-of-life in PDN patients.^36,37 Effects are typically observed as early as three to five days from drug initiation. It is associated with mild elevations of fasting plasma glucose and weight gain, but insignificant changes in hemoglobin A1c.³⁸ Adverse effects include gastrointestinal issues, somnolence, and hyperhidrosis.³⁶

Venlafaxine is an SNRI that is administered at a daily dose of 37.5-225 mg,²⁹ and functions as a selective serotonin reuptake inhibitor at low doses. While not FDA-approved for PDN, studies show significant pain improvement compared to placebo; however, there is comparatively better literature on the use of duloxetine in PDN, and thus venlafaxine should be considered only if duloxetine fails or the side effects are intolerable. Venlafaxine is noninferior to TCAs and gabapentin,³⁹ but inferior to pregabalin.⁴⁰ Adverse effects are similar to those of duloxetine; however, patients should also be routinely monitored for QTc prolongation.³⁹

TCAs, specifically amitriptyline, are also used in PDN management; however their use requires careful monitoring and tends to be avoided in elderly patients and those with significant comorbidities. Amitriptyline is administered daily at 25-150 mg.²⁹ Compared to duloxetine,^41,42 gabapentin,⁴³ and pregabalin,⁴⁴ amitriptyline confers noninferior pain relief. TCAs concurrently target histaminergic, adrenergic, and cholinergic receptors leading to a robust side effect profile, including gastrointestinal issues, orthostatic hypotension, dry mouth, urinary retention, and QTc prolongation.⁴² The use of this drug is recommended only as a last resort given its high risk of side effects.

Opioids

Chronic opioid therapy for PDN can be helpful for a subset of people; however, their use is associated with certain unique concerns. For example, now well-recognized is the concern of misuse and abuse with long-term opioid treatment: misuse is the use of a drug in a nonindicated manner, whereas abuse is when use becomes detrimental or unlawful.⁴⁵ Furthermore, it is important to understand the distinction between tolerance (physiological adaptation resulting in reduced drug efficacy) and physical dependence (physiological adaptation in which withdrawal can be induced with drug cessation or rapid dose reduction) with chronic opioid use.⁴⁵ Evaluating a person with PDN for the potential use of chronic opioid therapy should include obtaining a history of past/current substance abuse and addiction so that the prescriber can address all relevant issues before prescribing opioids.

Since the development of tolerance may lead to dose escalation, the prescriber needs to be aware of dose-dependent risks of opioid therapy. Opioids should always be used at the lowest effective dose. Side effects and aberrant behaviors must be monitored consistently by the prescriber and opioid-sparing approaches including interventional treatments need to be considered and routinely incorporated. Additional concerns of chronic therapy include the development of opioid-induced hyperalgesia—although not well understood, some patients will actually experience increased pain.⁴⁶ If identified, dose reduction can be very effective.

Tapentadol is an opioid that is FDA-approved specifically in PDN management as third-line therapy,⁴⁷ administered at an optimal dose of 100-250 mg twice daily. Several studies demonstrate that extended-release tapentadol significantly reduces pain intensity compared to placebo.^48-50 Levorphanol, a synthetic opioid, has also been reported to significantly reduce neuropathic pain when used in high-strength formulations (around 9 mg/day), with efficacy comparable to gabapentin and TCAs.⁵¹ Methadone, another synthetic opioid, has demonstrated efficacy in treating neuropathic pain, including patients who have previously failed trials of conventional opioids.⁵² Opioid-naïve patients are typically started at doses of 2.5-5 mg every 8-12 hours, and those patients currently taking other opioids require careful dose conversion.⁵³ Although effective for general neuropathic pain, both levorphanol and methadone require further studies to evaluate their use in PDN.

Topical Analgesics

Capsaicin is a topical analgesic utilized in low (0.075%) and high (8%) dose formulations for PDN management. Significant reductions in neuropathic pain intensity have been reported,^54,55 although results can be inconsistent.^56,57 Additional studies have reported 8% capsaicin as noninferior to pregabalin, duloxetine, and gabapentin with a comparatively more tolerable side effect profile.⁵⁵ Adverse effects include dermal irritation.⁵⁸ Qutenza is an 8% capsaicin patch approved for the treatment of PDN in Europe, and is currently pending FDA-approval.

Topical lidocaine (5%) can be utilized for the treatment of localized neuropathic pain,⁵⁹ with several studies demonstrating significant pain reduction, improvement in quality-of-life, and patient satisfaction compared to placebo.^60,61 Noninferiority testing with pregabalin, gabapentin, capsaicin and amitriptyline has demonstrated sustained efficacy with comparatively improved tolerability.^62,63 Side effects similarly include dermal irritation.⁶⁴

Other topical analgesics include ketamine cream and clonidine gel.⁶⁵ One study demonstrated that topical 5% ketamine did not improve PDN symptoms compared to placebo.⁶⁶ There is currently limited and inconsistent evidence on the clinical utility of clonidine for PDN.^67,68

Novel Agents

α-Lipoic acid is a potent antioxidant used in multivitamin formulas.⁶⁹ Its properties, including reduced oxidative stress, sustained microvascular blood flow, and improved nerve conduction velocity,^70,71 prompted investigation into its effects on PDN. Various placebo-controlled RCTs administered α-Lipoic acid with an oral or IV infusion of 600 mg once to thrice daily. Overall, improved neuropathic sensory symptoms were reported, without significant improvement in neuropathy impairment scores, levels of inflammatory or oxidative stress markers, or nerve conduction.^72-76 In the United States, it is available as a nutritional supplement and does not require a prescription. This has raised concerns regarding drug purity and safety.

Actovegin is a deproteinized ultrafiltrate of calf serum with potent anti-hypoxic effects. It has been investigated in several trials assessing a potential neuroprotective role in PDN, with regimens consisting of daily infusions (2000 mg) for 20 days followed by three times a day oral formulations (200 mg) for 140 days. These studies demonstrated improvement in neuropathic symptoms and vibration thresholds compared to placebo with a tolerable safety profile.^77,78 These novel agents require further investigation to further define their role in PDN management.

Intravenous Therapies

IV Lidocaine

Lidocaine is a local anesthetic with antiarrhythmic properties that also exerts analgesic effects. A recent systematic review evaluating IV lidocaine as a treatment for neuropathic pain reported superiority to placebo in the early post-infusion period.⁷⁹ However, infusions over four weeks had no further significant effect. While IV lidocaine was associated with an increased risk of minor adverse effects, no serious adverse effects were reported. Studies specific to the use of IV lidocaine for PDN were included in this review;^80-82 common infusion dosages were 5 and 7 mg/kg, providing varying degrees of pain relief from 10 to 28 days following infusion.

The effects of IV lidocaine are mainly limited to the immediate post-infusion period.^53,83,84 As such, its use may be better suited for acute adjunctive care while allowing for up-titration of oral analgesics to therapeutic dosages, as well as incorporation of nonpharmacologic modalities. Results are mixed, with other research showing no significant short- or long-term analgesic benefit up to four weeks post-infusion.⁸⁵ Overall, IV lidocaine is a safe alternative to opioid medications for acute management of PDN. Additional well-designed studies are needed to provide clear guidelines on clinical use.

IV Ketamine

Ketamine is a dissociative anesthetic that, when given in sub-anesthetic doses, has analgesic and anti-hyperalgesic effects. The duration of analgesic effect with a single dose of IV ketamine is approximately 60 minutes, and up to six hours when administered orally.⁵³ Although most studies have evaluated IV ketamine, oral administration has been reported to significantly improve neuropathic pain compared to methadone in one study.⁸⁶ A study evaluating patients with peripheral neuropathy treated with ketamine bolus and infusion reported a significant reduction in allodynia and spontaneous pain.⁸⁷ A recent systematic review showed that patients treated with IV ketamine demonstrated some type of pain relief for a variety of neuropathic pain syndromes, with comparatively poorer results for oral and topical administration.⁸⁸

In one study, the most common side effect was dizziness (44% for infusion, 22% for oral administration). Other side effects included sedation, loss of appetite, nausea, and vomiting.⁸⁹ Importantly, the use of IV ketamine has addictive potential similar to that of opioids. As it can be considered a drug of abuse, its use should be considered only in carefully selected patients, and under the strict supervision of a pain physician. Patient evaluation and screening should be similar to patients taking opioid therapy, including delineating a history of substance abuse and addiction. Overall, the use of ketamine in all forms for the treatment of PDN requires further study.

Neuromodulation

Neuromodulation therapies are nonablative pain treatments that are both titratable and reversible; these include intrathecal (IT) pain therapy and spinal cord stimulation (SCS). Both modalities have been demonstrated to be effective treatments option for neuropathic pain, including failed back surgery syndrome and complex regional pain syndrome (CRPS). However, few studies have assessed the use of IT therapy or SCS specifically in the treatment of PDN. Currently, the use of neuromodulation in the treatment of PDN is underutilized, which can be attributed to the lack of high-quality studies supporting its use, as well as limited referral to neuromodulation specialists. Accordingly, these are rare interventions that require careful consideration of a patient’s comorbidities and goals of therapy. Potential patients should be referred to a pain management specialist to determine their candidacy, and ideally their care should be discussed at a multidisciplinary pain conference. The use of neuromodulation therapies should be considered only following the failure of conservative management with evidence-based medications such as anticonvulsants and antidepressants.

Intrathecal Pain Therapy

The use of IT pain therapy is indicated for the treatment of chronic neuropathic pain, including peripheral neuropathy related to diabetes. Morphine (a µ-receptor agonist) and ziconotide (a nonopioid calcium channel blocker) are the only FDA-approved agents for the IT treatment of pain, and are both recommended by the Polyanalgesic Consensus Conference as first-line monotherapy in the treatment of localized or diffuse nonmalignant neuropathic pain.⁹⁰ IT therapies are recommended for the treatment of refractory pain, defined as a failure of conservative management with multiple evidence-based treatments.⁹¹ Importantly, IT therapy should not be used as salvage therapy following the failure of high-dose systemic opioids.⁹⁰ IT therapy can be used concurrently with oral therapies, and doses should be carefully managed by a pain specialist.

Ziconotide has certain advantages due to its nonopioid properties that make it a preferable first-line monotherapy. In particular, its use is not associated with an elevated risk of respiratory depression, and there is no withdrawal with abrupt discontinuation. However, a history of psychosis or concurrent use of anti-epileptics or sedatives is a contraindication.⁹² Initial IT dosing starts at 1.2 mcg/day, with titration of 1.1-2.8 mcg/day at two to four week intervals.⁹³

The use of IT morphine is also considered first-line; however, the risk of respiratory depression can be deadly, especially with the concurrent use of hypnotics or sedatives. Additional concerns include the development of tolerance, withdrawal with drug discontinuation or pump malfunction, and the rare development of a catheter tip granuloma which can cause neurological injury.⁹⁴ The recommended starting dosage for IT morphine is 0.1-0.5 mg/day, which should be titrated conservatively with consideration for the aforementioned side effects.⁹⁰

Tonic SCS

Conventional, tonic SCS utilizes low-frequency stimulation of 40-100 Hz to create paresthesias that overlaps painful anatomic regions.⁹⁵ In practice, lower extremity stimulation can typically be achieved with lead placement between T9-T11, although sometimes retrograde lead placement is required to achieve foot coverage. In the first clinical study of SCS in medically-refractory PDN, permanent SCS leads were implanted between T9-T11, with patients achieving significant pain relief at a median of 14 months, and with reduced or eliminated oral analgesic intake.⁹⁶ Significant long-term pain relief was demonstrated with follow-up at 3.3 and 7.5 years.⁹⁷ Similar small, uncontrolled studies demonstrated promising results with long-term SCS treatment.^98-100

The success of these pilot studies lead to the 2014 publication of two prospective, multi-center RCTs comparing the efficacy of conventional medical management with and without SCS.^101,102 In the study reported by de Vos et al, 36 PDN patients had SCS electrodes implanted between T9-T12.¹⁰¹ At six months follow-up, mean pain intensity was significantly decreased in the SCS group, with improved quality-of-life metrics and decreased analgesic intake. In the concurrent study by Slangen et al, 17 PDN patients underwent SCS implantation. Treatment success (≥50% improvement in pain severity) at six months follow-up was reported in 59% of SCS patients versus 7% of those receiving medical management alone.¹⁰² The patients in this latter study were reassessed at 24 months and continued to have sustained pain relief.¹⁰³

Sub-Paresthesia SCS

Although high-quality evidence has been reported for the use of tonic SCS in neuropathic pain, a significant proportion of patients in these studies did not achieve adequate pain relief. Subsequently, sub-paresthesia waveforms have been developed, including high-frequency and burst stimulation, in which minimal to no paresthesia is perceived.⁹⁵ Compared to tonic SCS, both high-frequency and burst SCS have been demonstrated to provide superior relief of back and leg pain in prospective RCTs.^104,105

There has been recent enthusiasm in applying these novel waveforms to improve the clinical outcomes of patients with PDN. The SENZA-PDN study is an ongoing prospective, multicenter RCT, with patients assigned to high-frequency SCS at 10 000 Hz plus medical management versus medical management alone (NCT03228420).¹⁰⁶ The primary endpoint is a composite measure of both safety and effectiveness at three months, with follow-up to continue for 24 months. Enrollment was recently completed in 2019, with preliminary results presented at the 2020 North American Neuromodulation Society Annual Meeting;¹⁰⁷ patients with PDN demonstrated improved pain severity, sleep, and walking tolerance at three months, and without higher rates of infection.

Dorsal Root Ganglion Stimulation

Conventional SCS targets the dorsal columns and thus has certain coverage limitations, and dorsal root ganglion (DRG) stimulation has emerged as a therapeutic modality to improve coverage of specific dermatomal distributions. Compared to tonic SCS, DRG stimulation in patients with complex regional pain syndrome has been reported to provide higher rates of treatment success.¹⁰⁸

As patients with PDN predominantly have lower extremity and foot pain, the specificity of coverage provided by DRG stimulation is attractive, although the current evidence is limited. In one retrospective study, seven PDN patients were implanted with a permanent system after a successful trial, and four patients with 12-month follow-up data reported a 64.16% mean relative reduction in perceived pain;¹⁰⁹ the majority of patients were implanted at L5. Based on dermatomal coverage, it is recommended to target L5, possibly with the addition of S1. A staged trial may consist of unilateral electrode placement, with the addition of bilateral electrode(s) for permanent implantation should the trial be successful. In clinical practice, the use of DRG stimulation may be preferable to dorsal column SCS due to its dermatomal specificity.

Other DRG studies have been preclinical. Using conventional and burst DRG stimulation in rat models of PDN, Franken et al observed attenuation of mechanical hypersensitivity using both waveforms compared to sham stimulation.^110,111 Although preliminary, these data suggest a potential role for DRG stimulation in the management of refractory PDN.

Other Stimulation Modalities

Despite being considered low-risk procedures, IT and SCS therapies are invasive and require the chronic implantation of hardware. Transcutaneous electrical nerve stimulation (TENS) is a noninvasive neuromodulation modality that delivers electricity via patches placed on painful areas, with efficacy demonstrated for some patients with musculoskeletal pain. The mechanism of action in PDN is unclear, and has been attributed to improved microcirculation and/or the stimulation of cutaneous afferents, leading to nociceptive inhibition.¹¹²

Some of the earliest studies evaluating TENS in the treatment of PDN reported decreased pain scores and improvement in neuropathic symptoms, although with a high placebo effect with sham stimulation.^113,114 Additional studied therapies include external muscle stimulation,^115,116 pulsed electromagnetic fields,¹¹⁷ and frequency rhythmic electrical modulation.¹¹⁸ Although multiple studies have been performed, they are limited by their short duration, small patient numbers, lack of study rigor, and significant placebo effects.¹¹²

Alternative Therapies

The use of nonpharmacological interventions for PDN has a great deal of support, and the most studied modalities include lifestyle modification with diet and exercise, dietary supplements, and holistic therapies such as yoga and acupuncture.¹¹⁹

Yoga has been reported to improve multiple health parameters in patients with diabetes including reduced BMI, systolic blood pressure, and fasting glucose, as well as a reduction in oxidative stress parameters.^120,121 In a study of older female patients with PDN, meditation and progressive relaxation resulted in significant daily pain reduction for at least 24 hours compared to baseline.¹²² Acupuncture has also been shown to be an effective treatment for PDN; one study reported significant pain relief when participants were treated once per week for 10 consecutive weeks with individualized acupuncture regimens.¹²³ Subsequent systematic reviews have reported favorable outcomes with acupuncture, although the practice is quite variable, employing different methodologies and outcome measures.^124,125

Low-level laser therapy (aka photobiomodulation) employs the use of red and near infra-red light over painful areas to purportedly improve tissue healing and promote pain relief. Some studies have demonstrated short-term pain relief in patients with PDN;^126,127 however, the lasting efficacy is unclear, with some studies reporting no benefit with longer-term follow-up.^128,129 As such, the use of alternative therapies should be integrated into a comprehensive management strategy and should not be used as sole interventions.

Conclusion

PDN is a relatively common complication of diabetes associated with significant disability and cost. Although primary prevention of diabetes is required at a societal level, the treatment of diabetic complications, including aggressive glycemic control, is essential in controlling the development of neuropathic complications. Guidelines exist regarding the pharmacological management of PDN, and first-line agents include anticonvulsants (pregabalin, gabapentin) and antidepressants (duloxetine). Oral opioids may be helpful in a subset of patients; however, their use should be carefully monitored, and should always be used at the lowest effective dose. Despite multiple conservative treatment options, there are considerable unmet needs in this patient population, and neuromodulation therapies, including IT drug delivery and SCS, have the potential to improve pain management outcomes. Improving pain outcomes will require an individualized patient approach, with consideration for pharmacotherapy, surgical treatments including neuromodulation, and other holistic alternative therapies.

Footnotes

Abbreviations

DRG, dorsal root ganglion; FDA, Food and Drug Administration; IT, intrathecal; PDN, painful diabetic neuropathy; RCT, randomized control trial; SCS, spinal cord stimulation; SNRI, serotoninnorepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TEN, transcutaneous electrical nerve stimulation.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Argoff is a Speakers Bureau member for Allergan, Inc., AstraZeneca Pharmaceuticals LP, Depomed, Inc., Iroko Pharmaceuticals, LLC, Millennium Laboratories, LLC, Teva Pharmaceuticals Industries Ltd., and XenoPort, Inc.; Advisory Board member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc., Depomed, Inc., Endo Pharmaceuticals Inc., Pfizer Inc., Purdue Pharma L.P., Shionogi & Co. Ltd., Teva Pharmaceuticals Industries Ltd., Vertex, and XenoPort, Inc.; Research support from Eli Lilly and Company, Endo Pharmaceuticals Inc., and Forest Laboratories, Inc. Dr Pilitsis is a consultant for Boston Scientific, Nevro, TerSera, Medtronic, Saluda and Abbott and receives grant support from Medtronic, Boston Scientific, Abbott, Nevro, TerSera, NIH 2R01CA166379-06 and NIH U44NS115111. She is medical advisor for Aim Medical Robotics and Karuna and has stock equity. All other authors declare no conflicts of interest.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Michael D. Staudt

References

Pop-Busui

Boulton

AJM

Feldman

, et al. Diabetic neuropathy: a position statement by the American diabetes association. Diabetes Care. 2017;40(1):136-154.

Hicks

Selvin

Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19(10):86.

Iqbal

Azmi

Yadav

, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828-849.

Feldman

Callaghan

Pop-Busui

, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41.

Gordois

Scuffham

Shearer

Oglesby

Tobian

JA.

The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790-1795.

Boulton

AJM

Vinik

Arezzo

, et al. Diabetic neuropathies: a statement by the American diabetes association. Diabetes Care. 2005;28(4):956-962.

Zafeiri

Tsioutis

Kleinaki

Manolopoulos

Ioannidis

Dimitriadis

. Clinical characteristics of patients with co-existent diabetic peripheral neuropathy and depression: a systematic review [published online ahead of print September 26, 2018]. Exp Clin Endocrinol Diabetes. doi:10.1055/a-0741-6937

Abbott

Malik

van Ross

ERE

Kulkarni

Boulton

AJM

. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220-2224.

Alleman

CJM

Westerhout

Hensen

, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015;109(2):215-225.

10.

Kiyani

Yang

Charalambous

, et al. Painful diabetic peripheral neuropathy: health care costs and complications from 2010 to 2015. Neurol Clin Pract. 2020;10(1):47-57.

11.

Bril

England

Franklin

, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American academy of neurology, the american association of neuromuscular and electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation. Neurology. 2011;76(20):1758-1765.

12.

Attal

Cruccu

Baron

, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.

13.

Griebeler

Morey-Vargas

Brito

, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639-649.

14.

Mai

Clark

Gordon

, et al. Long-term outcomes in the management of painful diabetic neuropathy. Can J Neurol Sci. 2017;44(4):337-342.

15.

Staudt

Clark

Gordon

, et al. Long-term outcomes in the management of central neuropathic pain syndromes: a prospective observational cohort study. Can J Neurol Sci. 2018;45(5):545-552.

16.

Ziegler

Rathmann

Dickhaus

Meisinger

Mielck

, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg surveys S2 and S3. Pain Med. 2009;10(2):393-400.

17.

Albers

Pop-Busui

Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473.

18.

American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(suppl 1):S124-S138.

19.

Ang

Jaiswal

Martin

Pop-Busui

Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528.

20.

Diabetes Control and Complications Trial Research Group, Nathan

Genuth

, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

21.

Finnerup

Attal

Haroutounian

, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.

22.

Snyder

Gibbs

Lindsay

TJ.

Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016;94(3):227-234.

23.

Azmi

ElHadd

Nelson

, et al. Pregabalin in the management of painful diabetic neuropathy: a narrative review. Diabetes Ther. 2019;10(1):35-56.

24.

Quilici

Chancellor

Löthgren

, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.

25.

Richter

Portenoy

Sharma

Lamoreaux

Bockbrader

Knapp

LE.

Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6(4):253-260.

26.

Arezzo

Rosenstock

Lamoreaux

Pauer

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.

27.

Tanenberg

Irving

Risser

, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc. 2011;86(7):615-626.

28.

Lesser

Sharma

LaMoreaux

Poole

RM.

Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104-2110.

29.

Rudroju

Bansal

Talakokkula

, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16(6):E705-E714.

30.

Moore

Wiffen

Derry

Toelle

Rice

ASC

. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;2014(4):CD007938.

31.

Hemstreet

Lapointe

Evidence for the use of gabapentin in the treatment of diabetic peripheral neuropathy. Clin Ther. 2001;23(4):520-531.

32.

Backonja

Beydoun

Edwards

, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-1836.

33.

Eisenberg

Lurie

Braker

Daoud

Ishay

Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57(3):505-509.

34.

Papanas

Ziegler

Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. Expert Opin Emerg Drugs. 2016;21(4):393-407.

35.

Gill

Derry

Wiffen

Moore

RA.

Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;2011(10):CD009183.

36.

Raskin

Pritchett

Wang

, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346-356.

37.

Wernicke

Pritchett

D’Souza

, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411-1420.

38.

Hardy

Sachson

Shen

Armbruster

Boulton

AJM

. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30(1):21-26.

39.

Rowbotham

Goli

Kunz

Lei

Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697-706.

40.

Razazian

Baziyar

Moradian

Afshari

Bostani

Mahmoodi

Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh). 2014;19(3):192-198.

41.

Kaur

Hota

Bhansali

Dutta

Bansal

Chakrabarti

A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34(4):818-822.

42.

Max

Lynch

Muir

Shoaf

Smoller

Dubner

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326(19):1250-1256.

43.

Morello

Leckband

Stoner

Moorhouse

Sahagian

GA.

Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159(16):1931-1937.

44.

Bansal

Bhansali

Hota

Chakrabarti

Dutta

Amitriptyline

vs.

pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med. 2009;26(10):1019-1026.

45.

Jamison

Mao

Opioid analgesics. Mayo Clin Proc. 2015;90(7):957-968.

46.

Rivat

Ballantyne

The dark side of opioids in pain management: basic science explains clinical observation. Pain Rep. 2016;1(2):e570.

47.

Patil

Wolfe

Said

Thomas

Martin

BC.

Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population. Clin J Pain. 2015;31(5):414-424.

48.

Schwartz

Etropolski

Shapiro

, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151-162.

49.

Niesters

Proto

Aarts

Sarton

Drewes

Dahan

Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113(1):148-156.

50.

Vinik

Shapiro

Rauschkolb

, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302-2309.

51.

Rowbotham

Twilling

Davies

Reisner

Taylor

Mohr

Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223-1232.

52.

Moulin

Palma

Watling

Schulz

Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci. 2005;32(3):340-343.

53.

Mendlik

Uritsky

TJ.

Treatment of neuropathic pain. Curr Treat Options Neurol. 2015;17(12):50.

54.

Simpson

Robinson-Papp

Van

, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42-53.

55.

van Nooten

Treur

Pantiri

Stoker

Charokopou

. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787-803.e18.

56.

Low

Opfer-Gehrking

Dyck

Litchy

O’Brien

PC.

Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain. 1995;62(2):163-168.

57.

Kulkantrakorn

Chomjit

Sithinamsuwan

Tharavanij

Suwankanoknark

Napunnaphat

0.075% capsaicin lotion for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial. J Clin Neurosci. 2019;62:174-179.

58.

Peppin

Pappagallo

Capsaicinoids in the treatment of neuropathic pain: a review. Ther Adv Neurol Disord. 2014;7(1):22-32.

59.

Casale

Symeonidou

Bartolo

Topical treatments for localized neuropathic pain. Curr Pain Headache Rep. 2017;21(3):15.

60.

Wolff

Bala

Westwood

Kessels

Kleijnen

5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand. 2011;123(5):295-309.

61.

Mick

Correa-Illanes

Topical pain management with the 5% lidocaine medicated plaster–a review. Curr Med Res Opin. 2012;28(6):937-951.

62.

Baron

Mayoral

Leijon

Binder

Steigerwald

Serpell

5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663-1676.

63.

Wolff

Bala

Westwood

Kessels

Kleijnen

5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21-22):297-306.

64.

Navez

Monella

Bösl

Sommer

Delorme

5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther. 2015;4(1):1-15.

65.

Javed

Petropoulos

Alam

Malik

RA.

Treatment of painful diabetic neuropathy. Ther Adv Chronic Dis. 2015;6(1):15-28.

66.

Mahoney

Vardaxis

Moore

Hall

Haffner

Peterson

MC.

Topical ketamine cream in the treatment of painful diabetic neuropathy: a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc. 2012;102(3):178-183.

67.

Wrzosek

Woron

Dobrogowski

Jakowicka-Wordliczek

Wordliczek

Topical clonidine for neuropathic pain. Cochrane Database Syst Rev. 2015;8(9):CD010967.

68.

Campbell

Kipnes

Stouch

, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815-1823.

69.

Shay

Moreau

Smith

Hagen

TM.

Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149-1160.

70.

Papanas

Ziegler

Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721-2731.

71.

Vallianou

Evangelopoulos

Koutalas

Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud. 2009;6(4):230-236.

72.

Ziegler

Low

Litchy

, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054-2060.

73.

Ziegler

Nowak

Kempler

Vargha

Low

PA.

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114-121.

74.

Mendoza-Núñez

García-Martínez

Rosado-Pérez

Santiago-Osorio

Pedraza-Chaverri

Hernández-Abad

VJ.

The effect of 600 mg alpha-lipoic acid supplementation on oxidative stress, inflammation, and RAGE in older adults with type 2 diabetes mellitus. Oxid Med Cell Longev. 2019;2019:3276958.

75.

Reljanovic

Reichel

Rett

, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy. Free Radic Res. 1999;31(3):171-179.

76.

Ametov

Barinov

Dyck

, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770-776.

77.

Ziegler

Edmundson

Gurieva

Mankovsky

Papanas

Strokov

Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. J Diabetes Complications. 2017;31(7):1181-1187.

78.

Ziegler

Movsesyan

Mankovsky

Gurieva

Abylaiuly

Strokov

Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479-1484.

79.

Zhu

Zhou

Wang

Luo

Intra-venous lidocaine to relieve neuropathic pain: a systematic review and meta-analysis. Front Neurol. 2019;10:954.

80.

Kastrup

Petersen

Dejgård

Angelo

Hilsted

Intravenous lidocaine infusion–a new treatment of chronic painful diabetic neuropathy?

Pain. 1987;28(1):69-75.

81.

Bach

Jensen

Kastrup

Stigsby

Dejgård

The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain. 1990;40(1):29-34.

82.

Viola

Newnham

Simpson

RW.

Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications. 2006;20(1):34-39.

83.

Wren

Lancaster

Walesh

, et al. Intravenous lidocaine for relief of chronic neuropathic pain. AANA J. 2019;87(5):351-355.

84.

Tremont-Lukats

Hutson

Backonja

M-M.

A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain. 2006;22(3):266-271.

85.

Moulin

Morley-Forster

Pirani

Rohfritsch

Stitt

Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. Can J Anaesth. 2019;66(7):820-827.

86.

Rigo

Trevisan

Godoy

, et al. Management of neuropathic chronic pain with methadone combined with ketamine: a randomized, double blind, active-controlled clinical trial. Pain Physician. 2017;20(3):207-215.

87.

Felsby

Nielsen

Arendt-Nielsen

Jensen

TS.

NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain. 1996;64(2):283-291.

88.

Aiyer

Mehta

Gungor

Gulati

A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain. 2018;34(5):450-467.

89.

Cvrcek

Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 2008;9(2):253-257.

90.

Deer

Pope

Hayek

, et al. The polyanalgesic consensus conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines [published online ahead of print January 2, 2017]. Neuromodulation. doi:10.1111/ner.12538

91.

Deer

Caraway

Wallace

MS.

A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17(8):711-715.

92.

Deer

Pope

Hanes

McDowell

GC.

Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain Med. 2019;20(4):784-798.

93.

Prusik

Argoff

Peng

Pilitsis

JG.

Use of low dose ziconotide as first-line intrathecal monotherapy. Neuromodulation. 2017;20(4):386-391.

94.

Deer

Pope

Hayek

, et al. The polyanalgesic consensus conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20(2):155-176.

95.

Sheldon

Staudt

Williams

Harland

Pilitsis

. Spinal cord stimulation programming: a crash course [published online ahead of print April 15, 2020]. Neurosurg Rev. doi:10.1007/s10143-020-01299-y

96.

Tesfaye

Watt

Benbow

Pang

Miles

MacFarlane

IA.

Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348(9043):1698-1701.

97.

Daousi

Benbow

MacFarlane

IA.

Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005;22(4):393-398.

98.

Kumar

Toth

Nath

RK.

Spinal cord stimulation for chronic pain in peripheral neuropathy. Surg Neurol. 1996;46(4):363-369.

99.

de Vos

Rajan

Steenbergen

van der Aa

Buschman

HPJ.

Effect and safety of spinal cord stimulation for treatment of chronic pain caused by diabetic neuropathy. J Diabetes Complications. 2009;23(1):40-45.

100.

Pluijms

Slangen

Bakkers

, et al. Pain relief and quality-of-life improvement after spinal cord stimulation in painful diabetic polyneuropathy: a pilot study. Br J Anaesth. 2012;109(4):623-629.

101.

de Vos

Meier

Zaalberg

, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155(11):2426-2431.

102.

Slangen

Schaper

Faber

, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016-3024.

103.

van Beek

Slangen

Schaper

, et al. Sustained treatment effect of spinal cord stimulation in painful diabetic peripheral neuropathy: 24-month follow-up of a prospective two-center randomized controlled trial. Diabetes Care. 2015;38(9):e132-e134.

104.

Kapural

Doust

, et al. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: the SENZA-RCT randomized controlled trial. Anesthesiology. 2015;123(4):851-860.

105.

Deer

Slavin

Amirdelfan

, et al. Success using neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation. 2018;21(1):56-66.

106.

Mekhail

Argoff

Taylor

, et al. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials. 2020;21(1):87.

107.

Petersen

Stauss

Scowcroft

, et al. 10 kHz spinal cord stimulation for treatment of painful diabetic neuropathy-a multicenter randomized controlled trial. North American Neuromodulation Society 23rd Annual Meeting; Las Vegas, NV, 2020.

108.

Deer

Levy

Kramer

, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 2017;158(4):669-681.

109.

Eldabe

Espinet

Wahlstedt

, et al. Retrospective case series on the treatment of painful diabetic peripheral neuropathy with dorsal root ganglion stimulation. Neuromodulation. 2018;21(8):787-792.

110.

Franken

Debets

Joosten

EAJ

. Dorsal root ganglion stimulation in experimental painful diabetic peripheral neuropathy: burst vs. conventional stimulation paradigm. Neuromodulation. 2019;22(8):943-950.

111.

Franken

Debets

Joosten

EAJ

. Nonlinear relation between burst dorsal root ganglion stimulation amplitude and behavioral outcome in an experimental model of painful diabetic peripheral neuropathy. Neuromodulation. 2020;23(2):158-166.

112.

Thakral

Kim

LaFontaine

Menzies

Najafi

Lavery

LA.

Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy. J Diabetes Sci Technol. 2013;7(5):1202-1209.

113.

Kumar

Marshall

HJ.

Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care. 1997;20(11):1702-1705.

114.

Kumar

Alvaro

Julka

Marshall

HJ.

Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. Diabetes Care. 1998;21(8):1322-1325.

115.

Reichstein

Labrenz

Ziegler

Martin

Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia. 2005;48(5):824-828.

116.

Humpert

Morcos

Oikonomou

, et al. External electric muscle stimulation improves burning sensations and sleeping disturbances in patients with type 2 diabetes and symptomatic neuropathy. Pain Med. 2009;10(2):413-419.

117.

Weintraub

Herrmann

Smith

Backonja

Cole

SP.

Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Arch Phys Med Rehabil. 2009;90(7):1102-1109.

118.

Bosi

Bax

Scionti

, et al. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial. Diabetologia. 2013;56(3):467-475.

119.

Baute

Zelnik

Curtis

Sadeghifar

Complementary and alternative medicine for painful peripheral neuropathy. Curr Treat Options Neurol. 2019;21(9):44.

120.

Hegde

Adhikari

Shetty

Manjrekar

D’Souza

Effect of community-based yoga intervention on oxidative stress and glycemic parameters in prediabetes: a randomized controlled trial. Complement Ther Med. 2013;21(6):571-576.

121.

Hegde

Adhikari

Kotian

Pinto

D’Souza

Effect of 3-month yoga on oxidative stress in type 2 diabetes with or without complications: a controlled clinical trial. Diabetes Care. 2011;34(10):2208-2210.

122.

Hussain

Said

ASA

. Mindfulness-based meditation versus progressive relaxation meditation: impact on chronic pain in older female patients with diabetic neuropathy. J Evid Based Integr Med. 2019;24:2515690X19876599.

123.

Bailey

Wingard

Allison

Summers

Calac

Acupuncture treatment of diabetic peripheral neuropathy in an American Indian community. J Acupunct Meridian Stud. 2017;10(2):90-95.

124.

Dimitrova

Murchison

Oken

Acupuncture for the treatment of peripheral neuropathy: a systematic review and meta-analysis. J Altern Complement Med. 2017;23(3):164-179.

125.

Nash

Armour

Penkala

Acupuncture for the treatment of lower limb diabetic peripheral neuropathy: a systematic review. Acupunct Med. 2019;37(1):3-15.

126.

Maiya

Hande

Vidyasagar

Rao

Rajagopal

KV.

Efficacy of low level laser therapy on painful diabetic peripheral neuropathy. Laser Ther. 2015;24(3):195-200.

127.

Swislocki

Orth

Bales

, et al. A randomized clinical trial of the effectiveness of photon stimulation on pain, sensation, and quality of life in patients with diabetic peripheral neuropathy. J Pain Symptom Manage. 2010;39(1):88-99.

128.

Zinman

Ngo

Nwe

Gogov

Bril

Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial. Diabetes Care. 2004;27(4):921-924.

129.

Ummer

Maiya

Hande

. Low level laser therapy for the patients with painful diabetic peripheral neuropathy - a systematic review. Diabetes Metab Syndr. 2019;13(4):2667-2670.

Current Strategies for the Management of Painful Diabetic Neuropathy

Abstract

Keywords

Introduction

Clinical Presentation and General Management

Pharmacotherapy

Anticonvulsants

Antidepressants

Opioids

Topical Analgesics

Novel Agents

Intravenous Therapies

IV Lidocaine

IV Ketamine

Neuromodulation

Intrathecal Pain Therapy

Tonic SCS

Sub-Paresthesia SCS

Dorsal Root Ganglion Stimulation

Other Stimulation Modalities

Alternative Therapies

Conclusion

Footnotes

Abbreviations

Declaration of Conflicting Interests

Funding

ORCID iD

References